Abstract: A pharmaceutical composition comprising a cancer therapeutic that is capable of inhibiting and/or reducing the ability of a cancer cell to take up and utilize glucose or other energy source, a lipid or other building block of a cell membrane or organelle, and/or cholesterol. The pharmaceutical composition can comprise one or more cancer therapeutics that can be administered individually or in combination to an individual.

Abstract: This invention refers to a pharmaceutical composition that comprises the synergic combination of a selective COX-2 inhibitor, such as the active ingredient: celecoxib and an anthraquinone derivative agent, such as the active ingredient: diacerein, which are formulated with pharmaceutically acceptable excipients and/or vehicles and/or additives in a single dosing unit to be administered by oral, parenteral, topical, transdermal means or with the use of transdermal, oral or nasal inhalation devices, which is indicated for the treatment of pain and inflammation in osteoarthritis, rheumatoid arthritis and/or degenerative joint disease caused by different etiologies.

Abstract: A method for treating a hyperhomocysteinemic subject having cerebral ischemic stroke generally includes administering to the hyperhomocysteinemic subject, following cerebral stroke, a composition that includes an inhibitor or an antagonist of a GluN2A-containing N-methyl-D-aspartate receptor (NMDAR) in an amount effective to ameliorate at least one symptom or clinical sign of cerebral stroke.

Abstract: The present invention relates to a liquid pharmaceutical preparation and a method for administering the pharmaceutical preparation by nebulization or soft mist inhalation. The pharmaceutical formulation comprises: (a) remdesivir or a pharmaceutically acceptable salt thereof; (b) an excipient selected from the group consisting of (i) a pharmacologically acceptable stabilizer or complexing agent and (ii) a solubility enhancing agent; and (c) a solvent wherein the pharmaceutical formulation has a pH of between about 2.0 and about 6.0.

Abstract: A method and composition including an effective amount of one or more synthetic neutral HMOs are disclosed for modulating the microbiota in the gastro-intestinal tracts of non-infant humans who are carriers of the human fucosyltransferase 2 (FUT2) genetic mutation and for improving one or more gastrointestinal conditions.

Abstract: The invention concerns composition comprising 2?-fucosyllactose for use in the treatment of virus induced diarrhea.

Abstract: The present invention discloses oral pharmaceutical compositions of Lactulose particularly useful to treat Constipation and hepatic encephalopathy. In particular, the present invention provides consumable, novel gummy delivery systems comprises Lactulose and methods of making the same. The composition comprises Lactulose, gelling agent, sweetener, buffering agents, flavouring agent, colouring agent, anti-tacking agent and preservative. Such gummy compositions for Lactulose may provide improved patient compliance relative to non-gummy compositions. Further the composition comprises Vitamin, nutritional supplements, minerals, antioxidants, soluble and insoluble fibre, herbs, plants, Probiotics, Pre-biotics amino acids, and digestive enzymes.

Abstract: A treatment for autism in which an effective amount of lactulose is administered in order to bind excess ammonia in the gastrointestinal tract, the bloodstream, and the nervous system in order to prevent or reverse ammonia poisoning caused by the administration of certain antibiotics. Lactulose molecules in the colon are fermented by certain bacteria. The fermentation process lowers the colonic pH, and ammonia, in the form of ammonium ions, is used by the bacteria for amino acid and protein synthesis. This lowers the serum ammonia levels and reduces neurotoxicity.

Abstract: A method of treating cancer in an individual includes a step of administering to the individual a pharmaceutically effective amount of (a) a first active agent adapted for producing secretion of prostate apoptosis response-4 (Par-4) from normal cells and (b) a second active agent adapted for elevating GRP78 receptors for Par-4 on a surface of a cancer cell in the individual.

Abstract: This disclosure relates to certain N4-hydroxycytidine derivatives, pharmaceutical compositions, and methods related thereto. In certain embodiments, the disclosure relates to the treatment or prophylaxis of human coronavirus 2019-nCoV.

Abstract: The invention relates generally to a pharmacological therapy for a human genetic diseases, specifically mitochondrial DNA depletion syndromes, and more specifically, thymidine kinase 2 (TK2) deficiency. The pharmacological therapy involves the administration of at least one deoxyribonucleoside monophosphate, or mixtures thereof. For the treatment of TK2 deficiency, the pharmacological therapy involves the administration of either deoxythymidine monophosphate (dTMP) or deoxycytidine monophosphate (dCMP), or mixtures thereof. This molecular bypass approach is applicable to other disorders of unbalanced nucleotide pools, especially those found in mitochondrial DNA depletion syndrome.

Abstract: The present invention relates to substituted purine and 7-deazapurine compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating disorders in which DOT1-mediated protein methylation plays a part, such as cancer and neurological disorders, by administering these compounds and pharmaceutical compositions to subjects in need thereof.

Abstract: The disclosure provides methods for the treatment of cancer in a subject comprising administering to the subject an inhibitor of Ubiquitin Conjugating Enzyme E2 K (UBE2K). The UBE2K inhibitor may be administered to the subject as a monotherapy, or in combination with an additional agent, such as an anticancer agent.

Abstract: A process for the preparation of hydroxocobalamin hydrochloride. More particularly the present application relates to improved process for the preparation of Hydroxocobalamin hydrochloride. In addition the present application also relates to process for the preparation of novel amorphous form. This application particularly relates to a process for the industrial manufacture of hydroxocobalamin hydrochloride from cyanocobalamin. The present application also relates to the improvement in yield with better purity of Hydroxocobalamin hydrochloride.

Abstract: The present disclosure relates to compositions and methods for the regeneration and/or restoration of hair cells utilizing a composition or an agent that decreases expression of a gene in a tissue of the inner ear and a second agent.

Abstract: Provided are compounds, methods, and pharmaceutical compositions for increasing the amount or activity of STMN2 RNA in a cell or animal, and in certain embodiments increasing the amount of STMN2 protein in a cell or animal. Such compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom of a neurodegenerative disease. Such symptoms include ataxia, neuropathy, synaptic dysfunction, deficits in cognition, and decreased longevity. Such neurodegenerative diseases include amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), Alzheimer's disease (AD), and dementia with Lewy bodies (DLB).

Abstract: Disclosed herein is the de novo synthesis of phosphorylated polyethylene glycol compounds with three defined ABA (hydrophilic/-phobic/-philic) structures: ABA-PEG10k-Pi10, ABA-PEG16k-Pi14, and ABA-PEG20k-Pi20 and linear polymer PEG20k-Pi20 absent of hydrophobic block. The disclosure also provides materials and methods for treating or reducing the risk or likelihood of developing, anastomotic leak or other microbe-mediated disorders by administering a therapeutically effective amount of a plasminogen inhibitor such as tranexamic acid and/or a phosphate-loaded polymer.

Abstract: Disclosed herein are compositions that can form a covering, layer, film, device, and/or prosthetic skin that can be comfortably worn to provide skin barrier function, skin hydration and therapeutic and aesthetic benefits. The present invention provides novel compositions that have low tackiness and form quickly, resulting in a wearable, comfortable (maintains temperature and humidity), breathable, thin, optically invisible, cosmetically elegant, flexible, stretchable, elastic and body-movement conforming, yet long-lasting covering, layer, film, device, and/or prosthetic skin on the skin or any other body surface. The present invention provides novel compositions that can form a covering, layer, film, device, and/or prosthetic skin that works for extended periods in excess of about 24 hours, while retaining function during and after exercising, showering and swimming (in sea-water, fresh water and chlorinated water), steam room (heat at high humidity), and sauna (heat at low humidity).

Abstract: The present disclosure provides a method for scavenging hydrogen peroxide and regulating gastrointestinal function by using a drinking water including silicon dioxide (SiO2).

Abstract: The present invention relates to a liquid nitric oxide releasing solution (NORS) comprised of at least one nitric oxide releasing compound and at least one acidifying agent, wherein the NORS provides an extended release of a therapeutically effective amount of nitric oxide gas (gNO). The present invention also relates to a liquid NORS comprised of at least one nitrite compound having a concentration of no greater than about 0.5% w/v and at least one acidifying agent, wherein the NORS releases a therapeutically effective amount of gNO. The present invention also relates to a method for the treatment of a wound in a human, the method comprising administering to the human a liquid NORS comprised of at least one nitric oxide releasing compound and at least one acidifying agent, wherein the NORS provides an extended release of a therapeutically effective amount of gNO.

Abstract: Inorganic anions nitrate and nitrite influence metabolic rate and glucose homeostasis. Infusion of nitrite iv caused an acute drop in resting energy expenditure (oxygen consumption) and nitrate, when given perorally, caused a reduction in oxygen consumption during exercise and a depression of the increase in blood glucose observed after an oral glucose tolerance test. The doses of nitrate and nitrite did not cause any detectable change in methemoglobin levels of blood. Also, nitrate and nitrite did not alter lactate levels in blood. This discovery provides useful treatments to regulate the energy expenditure and glucose homeostasis of a mammal by administration of inorganic nitrite and/or nitrate.

Abstract: Disease states such as cancer or virus infection appear to be dependent on supra-physiological levels of sulfane sulfur. This form of sulfur (sulfane sulfur, zero valent sulfur) has been shown to have numerous biological functions as a growth factor, metabolic regulator, and redox enhancer. It is generated in vivo from the sulfur-containing amino acids methionine and cysteine mainly via the polyamine pathway coupled to cysteine transamination with macrophages acting as an important source. Sulfane sulfur normally binds loosely to sulfur in proteins but it binds tightly to certain agents that have unused electron pairs such as sulfites, nitriles, or phophines. This provides a mechanism for binding and removing disease-related sulfane sulfur. The invention is particularly applicable to Covid-19 because this virus creates a “perfect storm” in which macrophages carry the virus docking site (ACE) and, at the same time, generate the sulfane sulfur required for invasion of the virus.

Abstract: A dietary supplement for treating side effects of medication which can cause metabolic acidosis includes calcium carbonate, ascorbic acid. The calcium carbonate including a total daily calcium carbonate amount of between 100 milligrams and 10 grams of calcium carbonate. The ascorbic acid including a total daily ascorbic acid amount between 200 milligrams and 6 grams milligrams of calcium carbonate. The supplement includes a frequency of daily doses of the supplement of between 1 and 6 doses daily of the supplement. The frequency of daily doses, the total daily calcium carbonate amount, and the total daily ascorbic acid amount being set based on a titration for symptoms of a patient.

Abstract: The present invention relates to the use of halogen compounds, including iodide, to treat and prevent Post-intensive care syndrome and skeletal muscle tissue damage resulting from an injury or disease.

Abstract: An aerosol containing fine droplets, the droplets separately or together containing a first component comprising an aqueous preparation of a transition metal or compound thereof and a second component which is an aqueous preparation containing at least one oxidation-reduction potential raising compound such as chlorite is useful in combating respiratory disorders and diseases caused by pathogens such as influenza, RSV, and coronavirus, as well as bacterial infections alone or associated with a viral pathogen.

Abstract: The present application relates to a method for reduction and prevention of damaged skin stasis comprising applying a material containing water-soluble or water-insoluble copper compounds to said damaged skin.

Abstract: A composition and process for use in wound healing and a process for making such a composition has a smectite gelling agent free of heavy and translon metals mixed with hydrogen peroxide and with water. The smectite gelling agent is a synthetic aluminosilicate having the formula (Na)x(Al2—XMgx)2Si2O10(OH)2.n(H2O) or Nax(Mg3—XLix)3Si4O10(OH)2 where X is between 0.1 and 0.5. The smectite gelling agent has a concentration between 1-7% w/w of the total composition. The hydrogen peroxide has a concentration of 1-6% w/w of the total composition. The smectite gelling agent, the hydrogen peroxide and water are mixed together in a mixer.

Abstract: Provided is a graphene quantum dot as a therapeutic agent for diseases associated with abnormal fibrillation or aggregation of neuroproteins. The graphene quantum dot according to the presently claimed subject matter suppresses ?-syn fibrillation or disaggregates already formed ?-syn fibrils, and shows the working effect of passing through the blood brain barrier (BBB). Therefore, the graphene quantum dot according to the presently claimed subject matter can be advantageously used as a therapeutic agent for diseases associated with abnormal fibrillation and aggregation of neuroproteins, such as neurodegenerative diseases, inflammatory diseases, and metabolic diseases.

Abstract: Dendritic cells containing tumor lysate loaded particles are prepared. The dendritic cells present tumor antigens to elicit the Major Histocompatibility Complex class I pathway and can be used as a vaccine to treat cancer, including ocular melanoma.

Abstract: The current invention provides monocytic cells transfected with chimeric antigen receptor (CAR) to selectively home to tumors and upon homing differentiate into dendritic cells capable of activating immunity which is inhibitory to said tumor. In one embodiment of the invention, monocytic cells are transfected with a construct encoding an antigen binding domain, a transcellular or structural domain, and an intracellular signaling domain. In one specific aspect of the invention, the antigen binding domain interacts with sufficient affinity to a tumor antigen, capable of triggering said intracellular domain to induce an activation signal to induce monocyte differentiation into DC.

Abstract: The embodiments relate to improved vitamin supplement compositions formulated for administration to patients, particularly improved vitamin compositions formulated for use in cosmetic or therapeutic applications. The compositions may be used to slow aging process and promote wellness including treating a vitamin deficiency, skin conditions, improving skin appearance, wound healing and scar prevention and hair loss.

Abstract: The present invention provides composition and methods for the treatment of cancer or infectious diseases in a human. The invention includes the generation and administration of gamma delta T cells that express chimeric antigen receptors (CARs) comprising an antigen binding domain, a hinge domain, a transmembrane domain, a costimulatory signalling domain with the inclusion or not of a CD3 zeta signalling domain. Expression of CAR sequence omitting the CD3 zeta signalling domain in gamma delta T cells, provides for a CAR-T therapy in vivo, which will effect cytolysis only on target cells providing ligands for activation of the gamma delta T cell receptor (TCR).

Abstract: Embodiments of the disclosure encompass methods and compositions related to cancer treatment with particular immune effector cells as adoptive immunotherapy and/or with soluble proteins to which the immune effector cells are able to bind. In some cases, the soluble proteins are molecular adaptors that allow targeting of cancer cells that lack expression of a tumor antigen to which the adoptive immunotherapy is directed. In some embodiments, the soluble proteins are exogenously provided as cytokine-cytokine receptor pairs that improve adoptive immunotherapy.

Abstract: The present disclosure provides binding proteins and TCRs with high affinity and specificity against Merkel cell polyomavirus T antigen epitopes or peptides, T cells expressing such high affinity Merkel cell polyomavirus T antigen specific TCRs, nucleic acids encoding the same, and compositions for use in treating Merkel cell carcinoma.

Abstract: The application relates to a chimeric antigen receptor that targets Eph receptors and allows activation of co-stimulatory pathways. The application also relates to polynucleotides that encode the chimeric antigen receptor, vectors, and host cells comprising the chimeric antigen receptor. The application also relates to methods for preparing host cells comprising a chimeric antigen receptor in order to improve the in vivo effector function of the chimeric antigen receptor host cells.

Abstract: The present disclosure relates to compositions and methods for treating cancer. For example, a modified cell may include a polynucleotide comprising an NFAT promoter, a nucleotide sequence encoding therapeutic agent, and a nucleotide sequence encoding a VHL-interaction domain of HIF1?, wherein the therapeutic agent comprises, for example, IL-12, IL-6, and/or IFN?.

Abstract: Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Abstract: The present disclosure provides methods for re-stimulating TIL populations that lead to improved phenotype and increased metabolic health of the TILs and provides methods of assaying for TIL populations to determine suitability for more efficacious infusion after re-stimulation.

Abstract: The present disclosure provides methods for re-stimulating TIL populations that lead to improved phenotype and increased metabolic health of the TILs and provides methods of assaying for TIL populations to determine suitability for more efficacious infusion after re-stimulation.

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Abstract: The present invention provides a chimeric antigen receptor (CAR) that recognizes CSPG4 as well as methods of use in the treatment of diseases and disorders.

Abstract: Disclosed herein are fusion fragment chimeric antigen receptors (FF-CARs), engineered cells expressing FF-CARs, and methods of using thereof to treat, reduce, or inhibit infections by enveloped viruses in subjects.

Abstract: Disclosed is a chimeric antigen receptor with improved persistency.

Abstract: Methods for producing megakaryocytes and platelets derived from inducible pluripotent stem cells and comprising a therapeutic agent are provided. The present disclosure further provides methods and compositions for loading a platelet or a megakaryocyte with a therapeutic agent and for genetically modifying a platelet or a megakaryocyte to express an agent.

Abstract: Methods and compositions comprising an isolated in vitro pre-conditioned population of placenta derived mesenchymal stem cells (PMSCs), wherein the PMSCs promote de novo regeneration of cartilage when the PMSCs are administered to a subject. A method of treating one of osteoarthritis, cartilage damage or loss, and pre-osteoarthritis in a patient comprising administering to the patient a pharmaceutical composition comprising an isolated in vitro pre-conditioned population of placenta derived mesenchymal stem cells (PMSCs), wherein the in vitro pre-conditioning comprises providing a population of mesenchymal stem cells from a placenta, and culturing the population of mesenchymal stem cells in a medium comprising soluble Notch ligand Jagged1 (JAG1); and a pharmaceutically acceptable carrier. A pharmaceutical composition comprising placenta derived mesenchymal stem cells (PMSCs), Notch ligand Jagged1 (JAG1), and a pharmaceutically acceptable carrier.

Abstract: In one aspect, engineered hematopoietic stem cells comprising a heterologous expression cassette are provided. In some embodiments, the expression cassette comprises a promoter operably linked to a polynucleotide that encodes a 1?-hydroxylase protein, wherein the 1?-hydroxylase protein is human cytochrome P450 family 27 subfamily B member 1 (CYP27B1).

Abstract: Disclosed herein are methods of administering an agent targeting a lineage-specific cell-surface antigen and a population of hematopoietic cells that are deficient in the lineage-specific cell-surface antigen for immunotherapy of hematological malignancies.